Body weight > 30 kg
Patients must have a body surface area (BSA) of >= 0.2 m^2 at the time of study enrollment
Patients must have a body surface area (BSA) >= 0.84 m^2
Patients must have a body surface area >= 0.35 m^2 at the time of study enrollment if enrolling on dose levels 1-5; patients must have a body surface area >= 0.46 m^2 at the time of study enrollment if enrolling on dose level 0
Body surface area (BSA) must be > 0.67 and < 2.5 m^2
Patients with a body surface area < 0.5 m^2 are not eligible
Patients who weigh < 10 kg are not eligible
Patients must have a body surface area >= 0.35 m^2
Patients must have a body surface area >= 0.65 m^2 at enrollment
Patients must have a body surface area >= 0.53 m^2 at enrollment
Patients must have a body surface area >= 0.5 m^2 at enrollment
Patients accruing to dose level 1 must have a body surface area >= 0.52 m^2 at the time of study enrollment; patients accruing to dose level 2 must have a body surface area >= 0.37 m^2 at the time of study enrollment; patients accruing to dose level -1 must have a body surface area >= 0.75 m^2 at the time of study enrollment
Weight ? 35 kg
Body surface area (BSA) >= 0.5 m^2
Prior total body or hemi-body irradiation
DONOR: Weight >= 20 kg and patient or guardian able to provide consent
A stem cell product collected prior to the infusion of 153Sm-EDTMP must be available, either by peripheral stem cell mobilization or bone marrow harvest prior to trial entry; a minimum of 2 x 10^6 cluster of differentiation (CD)34+ cells/kg ideal body weight is required
Patient with a BMI > 18 kg/m² and weighing at least 40 kg
DONOR: Donors who are not expected to meet the minimum target dose of marrow cells (1 x 10^8 nucleated cells/kg recipient ideal body weight)
Body surface area (BSA) ? 1.2 m2
Patients who will be receiving the tablet formulation must have a body surface area (BSA) >= 0.84 m^2 (square meter) at baseline.
Patients must have a body surface area >= 0.35 m^2 at the time of study enrollment
Each unit must have a minimum of 1.5 x 10^7/kg pre-cryopreserved total nucleated cell dose. For non-red blood cell depleted units, the minimum pre-cryopreserved total nucleated cell dose of each unit must be at least 2.0 x10^7/kg.
INCLUSION - PROCUREMENT: Weighs at least 12 kg
Adequate renal function with normal serum creatinine, or if creatinine above or below institutional normal range, a calculated glomerular filtration rate of ? 50 mL/min/1.73m2 (e.g., as calculated by the Cockcroft Gault formula) using actual body weight; if subject has body mass index > 30 kg/m2, lean body weight must be used.
Cord blood unit(s) must be matched at a minimum of 4/6 to the recipient at HLA-A and B at low resolution using DNA-based typing and HLA-DRB1 at high resolution using DNA-based typing. Based on a published report from Eurocord, for single unit transplantation, the single unit pre-cryopreserved total nucleated cell (TNC) dose must be a minimum of 4.0 x10^7/kg recipient weight. For double cord transplants, each unit must have a minimum of 1.5 x10^7/kg pre-cryopreserved TNC and a minimum total of 4.0 x10^7/kg (sum of unit 1 and unit 2). For non-red blood cell depleted units, the minimum pre-cryopreserved TNC dose is 2.0 x10^7/kg recipient weight. or
In the haplo cohort, the weight of the haplo donor must be ? 20 kg.
Weight ? 35 kg
DONOR: Age >= 4 and weight of >= 15 kg
Subjects must be at least 12 kg or 24 pounds to be eligible for stem cell donation
Subjects must be at least 12 kg or 24 pounds to be eligible for stem cell donation
Patients must weigh > (25 kg) at the time of study entry
Patients who weigh >= 50 kg
At least 15 kg
Patients who are 20% below their ideal body weight
ELIGIBILITY FOR SCREENING: Weighs at least 12 kg
Patient weight >= 100 kg; patients >= 70 kg with MUDs must be discussed with the principal investigator
Patients with a body weight < 110 pounds (lbs) (50 kilograms [kg]) because of the amount and frequency with which blood will be drawn, and because of the skin biopsies required.
Must be >= 10 kg
Arms C and D only: body surface area < 1.2 m2.
DONOR: weight of at least 35 kg
Subjects with baseline weight =< 40 kg (88 pounds [lbs]).
An actual body weight > 40kg
Has a body weight ? 40kg at the time of enrollment
Body weight >= 30 kg.
Weight over 40 kilograms (kg)
STRATUM B: Must meet the following weight and body surface area (BSA) restrictions:\r\n* For enrollment on dose level 0A, must have a weight  >= 16kg and < 32kg\r\n* For enrollment on dose level 0B must have a weight >= 32kg and BSA >= 0.55m^2\r\n* For enrollment on dose level 1, must have a weight >= 16kg and BSA >= 0.55m^2\r\n* For enrollment on dose level 2, must have a weight >= 16kg and BSA >= 0.63m^2\r\n* For enrollment on dose levels 3 or 4A, must have a weight >= 16kg \r\n* For enrollment on dose levels 4B or 5, must have a weight >= 20kg and =< 106kg
Body weight < 50 kilograms (110 pounds) or a body mass index ? 35 kg/m2.
Body weight > 30 kg.
Body weight > 30 kg
Patient body weight must be above the minimum necessary for the patient to receive the ONC201 dose indicated for the currently enrolling dose level. The minimum body weight ranges from 10 to 35kg depending on the dose level.
Patients must have a body surface area (BSA) of >= 1.17 m^2 at time of study enrollment
Patients must have a body surface area >= 0.87 m^2 at enrollment
Patients must have a body surface area (BSA) >= 0.55 m^2
Body surface area (BSA) greater than 0.3 m^2
Body weight of greater than or equal to (>=) 39 kilogram (kg) at Screening
Collection of an adequate number of CD34+ stem cells, i.e. >= 4-6 x 10^6/kg from apheresis
Have at least 3 million x 10e6 CD34+ cells/kg to be infused
Patients must weigh > 25 kg at the time of study entry
Body weight > 30 kg
Inability to purify >= 2.5 x 10^6 CD34-enriched cells/kg of patient weight from the pooled G-CSF mobilized leukapheresis products
Body weight > 35 kg
Body weight > 30 kg
Has undergone RIC allo BMT: cyclophosphamide (14.5 mg/kg/day) days ?6 and ?5, fludarabine (30 mg/m/day) days ?6 through ?2, total body irradiation (200 cGy) day ?1, day 0 infusion of an unmanipulated bone marrow graft (target 4.0 x 10^8 nucleated cells/kg recipient ideal body\r\nweight), cyclophosphamide (50 mg/kg) days +3 and +4, mycophenolate mofetil days +5 through +35, tacrolimus or sirolimus days +5 through days +180 based on protocol, and filgrastim (5 mcg/kg/day) day +5 through neutrophil recovery (> 1000/uLiter) following Hopkins BMT policy\r\nmanual guidelines
Weight < 30 kg
Body surface area (BSA) >= 0.55 m^2
Patients must have two cord blood (CB) units available which are matched with the patient at 4, 5, or 6/6 HLA\r\nclass I (serological) and II (molecular) antigens. Each cord must contain at least 1.5 x 10^7 total nucleated cells/Kg recipient body weight (pre-thaw).
Body weight of at least 40 kilograms
DONOR: At least 40 kilogram body weight
Weigh >=40 kg.
Body surface area (BSA): Subjects must have a body surface area ? 0.45 m2 at the time of the study enrollment, unless enrolled in Part E
> 40 kg
CELL PROCUREMENT: Pediatric subjects (weight must be >= 10 kg)
Weight over 40 kg
All races and ethnic groups will be included; for subjects between the ages of 12-18 years only, body surface area (BSA) must be >= 1.28 m^2
Stable dose of corticosteroids for 2 weeks prior to enrollment, i.e. the patient’s steroid dose (mg/kg) will remain unchanged (e.g. 0.5 mg/kg) in the 2 weeks preceding enrollment; allowances will be made for up or down titrating the dose based on changes in body weight
DONOR: Weight > 35 kg
Body surface area requirements varied by dose level: \r\n* Dose level: -1; body surface area (BSA): >= 0.82 m^2\r\n* Dose level: 1; BSA: >= 0.66 m^2\r\n* Dose level: 2; BSA: >= 0.52 m^2\r\n* Dose level: 3; BSA: >= 0.45 m^2
Patients must have at least 3 x 10^6 cluster of differentiation (CD)34+ cells/kg frozen
Subjects who weigh less than 45 kg
Patients with body weight < 30 kg
Body weight > 30 kg
Patients with a body surface area >3.0 m2.
Patients must be >= 15 kg
Body surface area > 2.0
Weight > 30kg (required for flat dose-based administration of study agents)
Less than or equal to 40 kg
PRIOR TO CELL PROCUREMENT: For pediatric subjects (weight must be ? 10 kg)
Minimum frozen PBSCs of 2 x 10^6 cluster of differentiation (CD)34 cells/kg for each transplant are mandatory and a PBSC of 2 x 10^6 CD34 cells/kg for back-up are strongly recommended (thus, PBSC of no less than 6 x 10^6 CD34 cells/kg is encouraged); these must all be collected prior to the initiation of consolidation
Patients must weigh greater than 30 kg
Weight ? 15 kg (33 lb)
Patients must have a body surface area >= 0.5 m^2 at enrollment
Patients with a weight of < 39 kg
Availability of >= 2.5 million cluster of differentiation (CD)34+ cells/kg previously apheresed
All patients eligible for therapeutic study must have (>= 2 x 10^6 CD34/kg) autologous hematopoietic stem cells harvested and cryopreserved
Patients must have a body surface area (BSA) of >= 0.42 m^2 at the time of study enrollment
Patients who receive greater than 12 mCi/kg are required to have stem cell rescue products harvested prior to study treatment; a minimum frozen autologous peripheral blood stem cell (PBSC) collection of 4 x 10^6 cluster of differentiation (CD)34+ cells/kg as 2 aliquots is the suggested dose; for subjects receiving < 12 mCi/ kg, a backup of 2.0 X 10^6 viable CD34+ cells/kg purged or unpurged PBSC is strongly recommended but not required
Body surface Area (For Dose Level -1): Patients must be ? 0.38 m² at the time of study enrollment.
Patients will be enrolled at collection of at least 3.0 x 10^6 CD34 cells/kg of autologous hematopoietic progenitor cells (HPC-A) by apheresis; a minimum of 2 collection procedures is required, unless collection on day # 1 > 5.0 x 10^6, CD34 cells/kg; a maximum of 10 collections is allowed; bone marrow harvest to supplement apheresis is not allowed
Prior failed (< 5 x 10^6 CD34/kg) peripheral blood stem cell (PBSC) collection
DONOR: Weight >= 40 kg
Patients weighing less than 50 Kg
Weight > 50 kg
DONOR: Cell yield goal (post CD34 determination): > 1-6 x10^6 CD34+ cells/kg recipient
If a patient does not have a hematopoietic stem cell product available for re-infusion after MIBG treatment, they may not receive a 131I-MIBG dose > 12mCi/kg; patients must have a hematopoietic stem cell product available for reinfusion after MIBG treatment at doses of > 12 mCi/kg; the minimum quantity for peripheral blood stem cells is 1.5 x 10^6 cluster of differentiation [CD]34+ cells/kg (optimum > 2 x 10^6 CD34+ cells/kg); the minimum dose for bone marrow is 1.0 x 10^8 mononuclear cells/kg (optimum > 2.0 x 10^8 mononuclear cells/kg)
Body weight < 3 kg.
Weight >40 kg (88 lb) and ?150 kg (330 lb); if between 13 and 14 years of age must weigh >= 50 kg (110 lb)
Must have 4-8 x 10^6 cluster of differentiation (CD)34+ cells/kg (recipient weight) infused on day 0
Must have at least one additional aliquot of >= 1 x 10^6 CD34/kg cryopreserved cells stored at the time of transplant
Availability of autologous peripheral blood stem cell graft, containing at least 6.0 x 10^6 cluster of differentiation 34 positive (CD34+) cells/kg
Patients must be >= 15 kg
Weighs at least 12kg
Patient must weigh a minimum of 8 kg
Patients will be enrolled after receiving at least two cycles of salvage cytoreductive chemotherapy and collection of at least 3.0 x 10^6 CD34 cells/kg of autologous hematopoietic progenitor cells (HPC-A) by apheresis; a minimum of 2 collection procedures is required, unless collection on day #1 > 5.0 x 10^6 CD34 cells/kg; a maximum of 10 collections is allowed; bone marrow harvest to supplement apheresis is not allowed
DONOR: Weight >= 40 kg
DONOR: Weight < 20 kg
A minimum apheresis collection of 5 million cluster of differentiation (CD)34+ cells/kg of autologous hematopoietic progenitor cells (AHPC)
DONOR: Selection of two CB units is mandatory when a single cord blood unit does not meet the following criteria in the table below\r\n* Match grade \r\n** 6/6\r\n*** Single unit allowed for total nucleated cell (TNC) dose >= 2.5 x 10^7/kg\r\n** 5/6, 4/6\r\n*** Single unit allowed for TNC dose >= 4.0 (+/- 0.5) x 10^7/kg\r\n* If two CB units are used, the total cell dose of the combined units must be at least 3.0 x 10^7 TNC per kilogram recipient weight based on pre-cryopreservation numbers, with each CB unit containing a MINIMUM of 1.5 x 10^7 TNC/kg
DONOR: The minimum recommended CD34/kg cell dose should be 2 x 10^5 CD34/kg, total dose from a single or combined double
In addition, each unit will have a cryopreserved dose of at least 1.5 x 10^7 total nucleated cells/recipient body weight (TNC/kg)
Highly-matched unrelated umbilical cord blood (UCB) (> 7/8 matches identified by high-resolution typing) accepted if a sibling donor is not able to donate bone marrow AND UCB with a sufficient number of nucleated cells (NCs) (i.e., > 1.5 x 10^7/kg recipient body weight [BW]) is cryopreserved
Must have ? 3 x 10^8 NCs/kg BW OR 3 x 10^6/kg BW CD34-positive cells available for transplantation
DONOR: Weight >= 20kg
Total Collection of >= 4 x 10^6 CD34 cells/kg prior to transplant one
INCLUSION CRITERIA FOR CCT: patients must have an autologous hematopoietic stem cell product cryopreserved and available for re-infusion after MIBG treatment; the minimum dose for peripheral blood stem cells is 2 x 10^6 CD34+ cells/kg
Body weight of greater than or equal to (>=) 39 kilogram (kg) at Screening
Body weight of greater than 30 kg
Clearance to be calculated using Cockcroft formula: Males: 1.23 x (140 - age) x weight (kg) - serum creatinine (?mol/l) ; Females: 1.05 x (140 - age) x weight (kg) - serum creatinine (?mol/l)
Adequate cell dose > 2.5x10^6 CD34+ cells/kg
The minimum dose for peripheral blood stem cells is: PURGED PBSC: 2.0 x 10^6 viable CD34+ cells/kg; UNPURGED PBSC: 2.0 x 10^6 CD34+ cells/kg (immunocytology is not required for peripheral blood stem cells)
For patients whose body weight exceeds ideal body weight (IBW) by more than 20%, adjusted body weight may be used for calculation of PBSC dose
Availability of autologous peripheral blood stem cell graft, containing at least 6.0 x 10^6 CD34+ cells/kg
Body weight > 30 kg
Body weight > 30 kg
DONOR: The minimum recommended CD34/kg cell dose is 1.7 x 10^5 CD34/kg
DONORS: Body weight of at least 40 kilograms
For subjects between the ages of 12-18 years only, body surface area (BSA) must be >= 1.5 m^2
Prior apheresis of >= 3 million CD34+ cells/Kg.
Body weight < 40 kg
The subject must weigh >= 35 kilogram (kg).
Participants who weigh > 110 kg will be ineligible due to study drug limitations
Adequate autologous stem cell collection, defined as an unmanipulated, cryopreserved, peripheral blood stem cell collection containing at least 2 x 10^6 cluster of differentiation (CD)34+ cells/kg based on patient body weight
Body surface area >= 1.4 m^2
DONOR: At least 40 kilogram body weight
Subjects must have collected at least 5 x 10^6 CD34+ cells/kg by apheresis after cycle 4
Has had a successful peripheral blood stem cell collection with G-CSF (filgrastim) +/- plerixafor (Mozobil) only; the target cell dose is >= 2.0 x10^6 CD34+ cells/kg
Patients must have a body surface area (BSA) of >= 0.53 m^2 at the time of study enrollment
Body surface area (for Parts A, B and C): \r\n* Patients must have a body surface area (BSA) of >= 0.42 m^2 at the time of study enrollment
Weight >= 15 kg
Weight < 30 kg
Patients must have a matched or partially matched UCB unit with >= 2.5 x10^7 nucleated cells/kg of recipient weight at the time of cryopreservation
All patients eligible for therapeutic study must have a minimum of >= 2 x 10^6 CD34/kg autologous hematopoietic stem cells harvested and cryopreserved
Part C: Patients must have a body surface area (BSA) >= 1.07 m^2 at the time of study enrollment
At least 15 kg
Patients with a body surface area (BSA) =< 0.4 m^2 are excluded
Autologous graft with a minimum of >= 3.0 x 10^6 CD34+ cells/kg; not CD34 selected
Patients receiving the formulated capsules must have a body surface area (BSA) >= 0.63 m^2 at the time of study enrollment
All patients eligible for therapeutic study must have a minimum of >= 4 x10^6 CD34/kg autologous hematopoietic stem cells harvested and cryopreserved and divided into 2 aliquots of at least >= 2 x10^6 CD34/kg each; patients with a history of prior autologous hematopoietic cell transplant (HCT) are only required to have >= 2x10^6 CD34/kg stored
Patients must have a dose of unpurged peripheral blood stem cells is 2.0 x 106 viable CD34+ cells/kg available.
Body weight < 40 kilograms
Body weight < 40 kilograms.
Weigh >55 kg
All patients eligible for therapeutic study must have a minimum of >= 2 x10^6 CD34/kg autologous hematopoietic stem cells harvested and cryopreserved
Body weight ? 175 kg.
Available autologous stem cells: >= 2 x 10^6 CD34+ cells/kg
Rash must cover less than 10% of body surface area (BSA)
Body surface area: the minimum body surface area (BSA) allowed for enrollment at dose level 1 to 0.85 m^2; the minimum for dose level 2 is BSA = 0.6 m^2 and the minimum for dose level 3 is BSA = 0.42 m^2
Body weight > 30 kilograms.
Patients weighing less than 30 kg
Body weight > 30 kg
To ensure that no patient will receive a dose of selinexor > 70 mg/m^2, body surface area (BSA) calculated by Dubois method must be > 1.43 m^2
Patients must have body surface area (BSA) > 0.55 m^2 at the time of enrollment\r\n* In the event of de-escalation from dose level 1 to dose level 0, patients with BSAs < 0.67 m^2 are not eligible
In the opinion of the investigator, patients who are significantly below their ideal body weight
Patient must be > 40 kg
Patients that in the opinion of the investigators are significantly below their ideal body weight
Body surface area (BSA) greater than 0.3 m^2
Body surface area (BSA) >= 0.5 m^2
Participants must have a minimum body surface area (BSA) of 0.6 m^2 at study entry, with the exception of one study arm which requires a minimum BSA of 1.33 m^2.
Patients who weigh >= 70 kg must be discussed with the principal investigator prior to enrolling on the protocol
Subject must weigh at least 20 kg
Patients will be treated at the same dose of tremelimumab as they previously received; for patients on dose level 1 who had already satisfied criteria for escalation to 10 mg/kg they will be re-treated at 10mg/kg
Age 15 and above and >40 kg.
Patients must have an adequate number of cluster of differentiation (CD)34+ stem cells collected to allow for transplantation (defined as >= 2 x 10^6 CD34+ cells/kg body weight); if not previously collected and stored or if previous collection was inadequate, the patients must be willing to undergo stem cell mobilization and collection as per standard practice
Body surface area >= 1.8m^2 on dosage levels 3b, 4, and 5 of the original treatment design
Body surface area < 0.55 m^2 for all dosage levels in the modified treatment design
Subjects must have a confirmed diagnosis of beta-thalassemia major and have been enrolled in a hypertransfusion program with a confirmed annual transfusion of >= 100 mL/kg/yr but < 200 mL/kg/yr, AND >= 8 transfusions of blood per year over a minimum of two years
DONOR: Weight (Wt) > 25 kg
Patients must have a body surface area (BSA) >= 0.4 m^2 at the time of study enrollment
Prior allogeneic or autologous stem cell transplant using a myeloablative busulfan or total body radiation containing conditioning regimen defined as busulfan-based using a total dose of >= 12 mg/kg given by mouth or >= 10 mg/kg given IV; or a total-body irradiation (> 4 Gy)
DONOR: At least 40 kilogram body weight
DONOR: Body weight of at least 40 kilograms
Subjects in whom the minimum stem cell dose of 5.0 x 10^6 CD34+ cells/kg has been collected
Body weight > 30 kg
Platelet count > 600 × 10^9/L after 3 months of at least 2 g/day of hydroxyurea (2.5 g/day in subjects with a body weight over 80 kg) OR at the subject's maximally tolerated dose if that dose is < 2 g/day.
Weight < 30 kg
PRIOR TO HIGH-DOSE CHEMOTHERAPY: Minimum of 2 x10^6 CD34+ cells/kg collected at mobilization
Able to collect >= 1.5 x 10^6 CD34+/kg cell for transplantation
Body surface area (BSA) >= 1.04 m^2
DONOR: Donors who are not expected to meet the minimum target dose of marrow cells (1 x 10^8 nucleated cells/kg recipient ideal body weight [IBW]) for the initial HCT; the average nucleated cell content of harvested marrow is 22 x 10^6 nucleated cells/mL or 220 x 10^8 nucleated cells/Liter
body weight which would preclude proper suprapubic catheter functioning, per investigator's discretion
Patients must have two cord blood units available which are matched with the patient at 4, 5, or 6/6 human leukocyte antigen (HLA) class I (serological) and II (molecular) antigens; each cord must contain at least 10 million total nucleated cells/Kg recipient body weight (pre-thaw)
DONOR: No contra-indication for the donor to collection by apheresis of mononuclear cells mobilized by G-CSF at a dose of 16 ug/kg of body weight
Subjects with a body weight > 140 kg (for Cohorts dosing 20 mg/kg of ALXN1007 and higher only).
No contraindication to the collection of a minimum of 4 x 10^6 CD34+ cells/kg by apheresis
Weight of at least 10kg.
Rash must cover less than 10% of body surface area (BSA)
Weight between 40 kg and 180 kg
Patients with adequate autologous stem cell collection for transplantation (target >= 2.5 x 10^6 CD34+ cells/kg)
Patients must have two cord blood (CB) units available which are matched with the patient at 4, 5, or 6/6 human leukocyte antigen (HLA) class I (serological) and II (molecular) antigens; each cord must contain at least 1.5 x 10^7 total nucleated cells/kg recipient body weight (pre-thaw)
Weight >= 45 kg
Patients whom, in the opinion of the investigators, are significantly below their ideal body weight
Body surface area (BSA) ? 2.4 m2.
Body weight >= 45 kilogram (kg) and a body mass index >= 19 kilogram per squaremeter (kg/m^2)and <40 kg/m^2 (inclusive);
Adequate autologous graft, defined as an unmanipulated, cryopreserved, peripheral blood stem cell graft containing at least 2 x 10^6 cluster of differentiation (CD)34+ cells/kg based on patient body weight
In the opinion of the investigator, patients who are significantly below their ideal body weight
Weight ?3rd percentile for age and gender (and ?3.0 kg)
Patients age 16-17 years are eligible only if they have a body surface area (BSA) >= 1.7 m^2 or weigh >= 60 kg
In the opinion of the investigator, patients who are significantly below their ideal body weight.
Patients who are 13 years old or older and have more than 45 kg of body weight will be eligible after consultation with their pediatric attending
Body weight < 35 kg (77 pounds)
> 10 kg at the time of apheresis; patients between 10-15 kg. must be approved by the apheresis unit prior to enrollment on protocol
Weight ? 34 kg.
Skeletally mature adolescents must weigh at least 45 kg
Body weight > 30 kg
Patients must have a body surface area >= 0.35 m^2 at the time of study enrollment
Body weight > 150 kg
Availability of previously collected autologous stem cells (at least 3.0 x 10^6 cluster of differentiation [CD]34 cells/kg)
Weight >= 45 kg
Patients weighing < 40 kg
Weight > 10 kg (22 lbs)
Patients must be undergoing a myeloablative allogeneic hematopoietic cell transplant with one of the following conditioning regimens:\r\n* Busulfan (>= 12.8 mg/kg IV or PO) and cyclophosphamide (>= 120 mg/kg)\r\n* Total body irradiation (TBI) (>= 1200 cGy) and etoposide (60 mg/kg)\r\n* TBI (>= 1200 cGy) and cyclophosphamide (120 mg/kg)
In order to limit dose deviations due to rounding, patients must have a body surface area of at least 0.5 m^2
Patient weight >= 50 kg
All patients must have an accurate pre-op height and weight and BSA (body surface area) calculation for CO (cardiac output) monitoring on FloTrac
Patients < 55 kg or > 140 kg, based on literature regarding accuracy of FloTrac
Overweight or obese (> 25 kg/m^2)
Area to be irradiated representing 1-10% of total body surface area (TBSA)
Patients whose BMI falls outside the eligible range (< 25 kg/m^2 or > 33 kg/m^2)
Obesity (body weight > 140 Kg)
Must weigh 20 kg
Patients weighing < 50 kg
Body weight must be >= 20 kilograms (kg) if suspension is not available
The patient must weigh less than 150 kg (330 lb), which is the limit of the imaging couch
Weight > 110kg
Patient must have cluster of differentiation (CD)34+ stem cells >= 2 x 10^6/kg (actual body weight of the recipient) available for transplantation
Subjects must have CD34+ collection which allows reinfusion of ?1.5 x 106 and ?5.0 x 106 CD34+ cells/kg
Patients who have not shown a satisfactory response to methylprednisolone-equivalent doses at 2 mg/kg/day, based on adjusted body weight
weight of less than or equal to 45 kg (for sites using cefuroxime only).
BSA (Body Surface Area) of <0.25 m2.
Weight between 50 kg to 130 kg
Patient weight at least 3.3 kg.
Body Surface Area (BSA) (m2) of <0.25
Weigh more than 18 kg
Body weight > 30 kg
Subjects whose body surface area (BSA) would expose them to < 75% or > 125% of the target dose
Normal weight (BMI < 25.0 kg/m^2)
Subjects weighing > 136 kg (weight limit for scanner table)
Body weight >= 400 pounds or body habitus or disability that will not permit the imaging protocol to be performed
Body weight between 50 kg (110 lb) and 110 kg (243 lb), inclusive
Participants with severe claustrophobia not relieved by oral anxiolytic medication or patients weighing > 136 kg (weight limit for scanner table)
Subjects weighing > 136 kg (weight limit for scanner)
Body weight greater than 350 lbs (158 Kg)
Patients who weigh > 70 kg are excluded; in addition, patients who weigh > 136 kg are excluded
Body weight > 137 Kg (300 lbs)
Body weight greater than 350 lbs (158 Kg)
Body Surface Area < 1.4 m2 at baseline, calculated by the Dubois or Mosteller method.
Subjects weighing > 136 kg (weight limit for scanner table)
Patient weighs > 30 kg
Unexplained change in weight (> 4.5 kg) within the past 6 months
